CYP21A2 and hyperandrogenism: Women with hyperandrogenism are more frequently identified as heterozygous gene carriers for a non-classic CYP21A2 mutation than in the general population [42, 43], but to date, there is no precise explanation for the symptoms described in the heterozygous patients [44].